ezetimibe has been researched along with Constriction, Pathological in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Christian Schulze, P; Friedrichs, S; Kerksiek, A; Lütjohann, D; Möbius-Winkler, S; Otto, S; Pörner, TC; Weingärtner, O | 1 |
| Bang, CN; Boman, K; Eugen-Olsen, J; Forman, JL; Greve, AM; Hodges, GW; Jeppesen, JL; Kesäniemi, YA; Olsen, MH; Ray, S; Wachtell, K | 1 |
1 trial(s) available for ezetimibe and Constriction, Pathological
| Article | Year |
|---|---|
Effect of simvastatin and ezetimibe on suPAR levels and outcomes.
Topics: Aged; Anticholesteremic Agents; Aorta; Aortic Valve Stenosis; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Constriction, Pathologic; Disease Progression; Ezetimibe; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Receptors, Urokinase Plasminogen Activator; Risk Factors; Simvastatin | 2018 |
1 other study(ies) available for ezetimibe and Constriction, Pathological
| Article | Year |
|---|---|
Increased cholesterol absorption is associated with In-stent-restenosis after stent implantation for stable coronary artery disease.
Topics: Cholesterol, LDL; Constriction, Pathologic; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Ezetimibe; Female; Gas Chromatography-Mass Spectrometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Phytosterols; Stents; Triglycerides | 2022 |